Antisense Oligonucleotides: An Emerging Frontier in Genetic Therapy

Abstract

Antisense oligonucleotides (ASOs) signify an exciting development in genetic therapy, utilizing short, synthetic RNA or DNA strands to modulate gene expression and address a variety of diseases. These strands, which are 12-24 bases in length, attach to target RNA molecules through Watson-Crick base pairing, allowing for precise regulation of genes responsible for diseases and their variants. The advancement of ASO technology has been greatly impacted by progress in understanding RNA structures, creating efficient delivery systems, and making chemical modifications that improve stability and effectiveness. As a new category of therapeutics, ASOs provide an option beyond traditional protein-targeted treatments by directly addressing the genetic origins of diseases. Importantly, most ASOs are being developed for rare genetic disorders, which can be extremely disabling and currently have few effective therapies available. With their distinct method of action and ability to transform the treatment of previously challenging conditions, ASOs offer significant potential for changing the field of genetic therapy and enhancing patient outcomes. This developing area is set to push the limits of therapeutic advancements, bringing new hope to patients and families dealing with genetic disorders.